Based on these findings, current clinical trials are investigating the combination of CDK4/6 inhibitors and immune checkpoint inhibitors [16]; this strategy may increase the response to immunotherapy in estrogen-receptor-positive (ER+) BC, which showed only minimal response to the use of checkpoint inhibitors as single agents [36]. This evidence concerns the gene ESR1 and breast cancer.